Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Goenback sesame extract, also known by the research code HL-JOINT 100, is a proprietary botanical extract derived from sesame seeds (*Sesamum indicum*) and developed by the South Korean company HL Science. Standardized to high concentrations of the lignans sesamin and sesamolin, the extract is primarily indicated for the maintenance of joint and cartilage health. Its mechanism of action involves the down-regulation of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), as well as the inhibition of matrix metalloproteinases (MMPs) such as MMP-1, MMP-3, and MMP-13, which are responsible for cartilage degradation. Clinical studies have demonstrated its ability to improve joint function and reduce pain scores in patients with osteoarthritis. In 2018, it received recognition from the South Korean Ministry of Food and Drug Safety (MFDS) as a functional health food ingredient for joint and cartilage health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Goenback sesame extract.